Author

Delia Rota‐Scalabrini

Observed names: D Rota-Scalabrini, D. Rota-Scalabrini, D. Rota‐Scalabrini, Delia Rota-Scalabrini, Delia Rota–Scalabrini

Observed institutions: Azienda Ospedaliera Citta' della Salute e della Scienza di Torino, Azienda Ospedaliero Universitaria San Giovanni Battista, Fondazione Gimema Onlus, Fondazione Intergruppo Italiano Linfomi Onlus, Candiolo Cancer Institute, Fondazione Piemontese per la Ricerca sul Cancro Onlus, University of Turin

ORCID: 0000-0003-0744-6390

Observed ORCID: 0000-0003-0744-6390

OpenAlex ID: A5042850515

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program

2013 · Marco Ladetto, Chiara Lobetti-Bodoni, et al. · Blood · 102

PDF

High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

2022 · Luca Bertamini, Stefania Oliva, et al. · Journal of Clinical Oncology · 100

PDF

Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial

2022 · Roberto Mina, Pellegrino Musto, et al. · The Lancet Oncology · 97

PDF

Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma

2021 · Alessandra Larocca, Francesca Bonello, et al. · Blood · 93

PDF

Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study

2013 · Alessandra Larocca, Vittorio Montefusco, et al. · Blood · 87

PDF

Post-Transplant Cyclophosphamide and Tacrolimus–Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors

2016 · Fabrizio Carnevale-Schianca, Daniela Caravelli, et al. · Transplantation and Cellular Therapy · 64

Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study

2009 · U. Vitolo, A. Chiappella, et al. · Haematologica · 64

PDF

Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma

2023 · Mattia D’Agostino, Giuseppe Bertuglia, et al. · Blood · 44

PDF

Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial

2023 · Elena Zamagni, Stefania Oliva, et al. · EClinicalMedicine · 44

PDF

Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial

2019 · Sara Bringhen, Mattia D’Agostino, et al. · Haematologica · 43

Complete Resolution of Life-Threatening Bleomycin-Induced Pneumonitis After Treatment With Imatinib Mesylate in a Patient With Hodgkin's Lymphoma: Hope for Severe Chemotherapy-Induced Toxicity?

2011 · Fabrizio Carnevale-Schianca, Susanna Gallo, et al. · Journal of Clinical Oncology · 42

PDF

Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin’s lymphoma patients: A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL)

2012 · Luigi Rigacci, Benedetta Puccini, et al. · Annals of Hematology · 38

Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing

2023 · Stefania Oliva, Elisa Genuardi, et al. · EClinicalMedicine · 33

PDF

Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial

2021 · Umberto Ricardi, Mario Levis, et al. · Blood Advances · 32

Carfilzomib-based induction/consolidation with or without autologous transplant (ASCT) followed by lenalidomide (R) or carfilzomib-lenalidomide (KR) maintenance: Efficacy in high-risk patients.

2021 · Francesca Gay, Roberto Mina, et al. · Journal of Clinical Oncology · 26

Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study

2011 · Emilio Iannitto, Fortunato Morabito, et al. · British Journal of Haematology · 21

PDF

Post-Transplant Cyclophosphamide and Tacrolimus—Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors

2021 · Fabrizio Carnevale-Schianca, Daniela Caravelli, et al. · Journal of Clinical Medicine · 20

PDF

Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial

2019 · Riccardo Bruna, Fabio Benedetti, et al. · Haematologica · 20

PDF

MACOP-B treatment for advanced stage diffuse large cell lymphoma: A multicenter Italian study

1989 · Umberto Vitolo, Marilena Bertini, et al. · European Journal of Cancer and Clinical Oncology · 20

Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells

2024 · Mattia D’Agostino, Delia Rota-Scalabrini, et al. · Blood Cancer Journal · 14

Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial

2021 · Roberto Mina, Antonietta Pia Falcone, et al. · Blood Cancer Journal · 14

PDF

A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and ‘on-demand’ plerixafor in multiple myeloma patients treated with novel agents

2023 · Roberto Mina, Maria Teresa Petrucci, et al. · Haematologica · 13

Mitoxantrone, etoposide, cisplatin and dexamethasone (MEPD) as salvage chemotherapy in resistant non-Hodgkin's lymphoma.

1991 · U Vitolo, L Orsucci, et al. · PubMed · 9

Antibody Therapies for Large B-Cell Lymphoma

2021 · Mattia Novo, Elisa Santambrogio, et al. · Biologics · 8

PDF

Early Mortality in Elderly Patients With Newly Diagnosed Multiple Myeloma Treated With Novel Agents

2015 · A. Larocca, S. Bringhen, et al. · Clinical Lymphoma Myeloma & Leukemia · 7

Works count: 48

Citation count: 1,093

H-index: 19

I10-index: 22